A Study Of Epidemiology, Mechanistic Pathways, And Outcomes Of Propofol-Associated Hypertriglyceridemia
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 26-003807
About this study
The purpose of this study is to define the true epidemiology, mechanistic pathways, and causal relationships of propofol-associated hypertriglyceridemia through the first prospective observational cohort with systematic triglyceride monitoring.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Age ≥18 years
Admitted to an adult ICU at Mayo Clinic Rochester
Currently on mechanical ventilation receiving continuous propofol infusion
Has been on mechanical ventilation with propofol for at least 24 hours
The clinical team expects the patient to remain intubated
No active plans for transition to comfort care measures
Legally authorized representative available for consenting (if patient lacks decision-making capacity)
Exclusion Criteria:
Transfer from an outside hospital where propofol was already being administered at the time of ICU admission (rationale: unable to obtain baseline pre-propofol triglyceride level from stored pre-intubation specimens)
Anticipated extubation within 24 hours of screening (rationale: insufficient time to observe P-HTG development and resolution patterns)
Patient or LAR declines participation
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 04/06/2026. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Hemang Yadav, M.B.B.S. |
Contact us for the latest status |
|
More information
Publications
Publications are currently not available